Measurement of Immunoglobulin A and Immunoglobulin M and their relation to treatment outcome of Immune Thrombocytopenic Purpura

Abstract

Primary immune thrombocytopenia, or idiopathic thrombocytopenic purpura (ITP), is an autoimmune disorder characterized by isolated thrombocytopenia due to accelerated platelet destruction and impaired platelet production. Autoantibodies against platelet surface glycoproteins (GP), such as GPIIb/IIIa and GPIb/IX complexes, play major roles in both platelet destruction and impaired platelet production. The diagnosis of ITP is a process of exclusion. First, it has to be determined that there are no blood abnormalities other than a low platelet count, and no physical signs other than bleeding. Then, secondary causes (5–10 percent of suspected ITP cases) should be excluded. Although corticosteroids and splenectomy remain central to the treatment of ITP, a new class of drugs, i.e., thrombopoietin receptor agonists (TPO-RAs) and rituximab, have substantially broadened the therapeutic options for refractory ITP patients. In our study we enrolled about 60 newly diagnosed ITP patients aged from 16-65yrs from hematology department at ain shams university hospital prospectively from February 2017 to January 2018 after taking an informed consent.